Retour sur le Paris PSVD Meeting !
The Paris PSVD Meeting brought together the international PSVD community for two days of high-level scientific exchange and collaboration.
Le Paris PSVD Meeting a réuni la communauté internationale de la PSVD pour deux journées d’échanges scientifiques et de collaboration.
The Paris PSVD Meeting was the first international scientific meeting dedicated to Porto-Sinusoidal Vascular Disease (PSVD) and aimed at healthcare professionals.
Organised by EURO-VALDI-NET and the FILFOIE network, this exceptional two-day conference took place at the Conservatoire National des Arts et Métiers (CNAM) in Paris on December 4–5, 2025.
The conference gathered international experts to discuss key aspects of PSVD, including pathophysiology, diagnosis, prognosis, and therapeutic management, offering a comprehensive and multidisciplinary perspective on this rare vascular liver disease.
It featured more than 20 speakers and welcomed more than 100 on-site participants, with over 300 additional attendees joining remotely.
The organisers warmly thank COST Action, ERN RARE-Liver, SNFGE and AFEF for their support, as well as EASL, BAVENO, ALEP, AASLD and AEEH for their valuable contribution to the meeting.
The replays of the sessions are now available, and all presentations can be accessed below.
All presentations are available in PDF format below.
– DAY 1 –
Session 1: Pathophysiology and conditions associated with PSVD
- Conditions associated with PSVD; impact on prognosis and impact of their treatment on PSVDCauses and underlying mechanisms – Filipe NERY – Portugal
- Genetics and PSVD – Silvia VILARINHO – USA
- Pathophysiology: is PSVD an immune, a vascular or acoagulation disorder? – Marco SENZOLO – Italy
- Preclinical models of PSVD – Genís CAMPRECIÓS – Spain
Session 2: Diagnosis and Natural history of PSVD
- When should PSVD be suspected? – Laure ELKRIEF – France
- PSVD without portal hypertension – Pierre DELTENRE – Belgium
- Prognostic and natural history of PSVD with signs of portalhypertension – Juan-Carlos GARCIA-PAGAN – Spain
Session 3: Diagnostic tools in PSVD
- Imaging and PSVD: how to improve diagnosis and prognostic? – Maxime RONOT – France
- Pathological changes in PSVD: current view and future directions – Valérie PARADIS – France, Alexandre SAYADI – France
Session 4: Challenges in PSVD
- Can PSVD regress? – Andrea DE GOTTARDI – Switzerland
- Can PSVD lead to cirrhosis? – Theo HELLER – USA
- Nodules in PSVD – Christine SEMPOUX – Switzerland
Session 5: Management of PSVD
- Hemodynamic changes in PSVD and their modulation – Lucile MOGA – France
- Management of complications of portal hypertension in PSVD: should that really be the same as in cirrhosis? – Michael PRAKTIKNJO – Germany
- Liver transplantation in PSVD – Sarwa DARWISH-MURAD – Netherlands
- Specificities of PSVD in children and transition to adulthood – Angelo DI GIORGIO – Italy
– DAY 2 –
Session 1: Break out session on clinical trials in PSVD
1/ Inclusion criteria for studies on PSVD
Moderator: Laure ELKRIEF – France
Panelists: Juan-Carlos GARCIA-PAGAN – Spain, Aurélie PLESSIER – France, Andrea DE GOTTARDI – Switzerland, Maxime RONOT – France, Christine SEMPOUX – France, Luis TÉLLEZ – Spain, Emmanuel GONZALES – France, Raymundo PARANA – Brasil, Moira HILSCHER – USA, Venâncio ALVES – Brasil
2/ Surrogate markers of outcome in PSVD: do’s and don’ts
Moderator: Pierre-Emmanuel RAUTOU – France
Panelists: Elton DAJTI – Italy, Annalisa BERZIGOTTI – Switzerland, Necati ÖRMECI – Turkey, Eira CERDA – Mexico, Laura TURCO – Italy,
Fanny TURON – Spain, Akash SHUKLA – India, Ansgar LOHSE – Germany, Anna BAIGES – Spain, Valérie PARADIS – France, Maxime RONOT – France, Lucile MOGA – France
3/ Hard endpoints in PSVD studies
Moderator: Virginia HERNANDEZ-GEA – Spain
Panelists: Christophe BUREAU – France, Jonel TREBICKA – Germany,Dominique VALLA – France, Sarwa DARWISH MURAD –
Netherlands, Dhiraj TRIPATHI – UK, Angela PUENTE – Spain,Elizabeth VERNA – USA, Marco SENZOLO – Italy, Erica VILLA – Italy
Session 2: Innovations for clinical trials in PSVD
- Innovative trial design for rare diseases – Lucie BIARD – France
- HRQOL and PRO in patients with PSVD – Agnès DUMAS – France, Aurélie PLESSIER – France, Patient
representative
Session 3
- Novel therapies and therapeutic approaches – Pierre-Emmanuel RAUTOU – France
- Feed-back from the working groups: Inclusion criteria for studies on PSVD – Laure ELKRIEF – France
- Feed-back from the working groups: Surrogate markers of outcome inPSVD: do’s and don’ts – Pierre-Emmanuel RAUTOU – France
- Feed-back from the working groups: Hard endpoints in PSVD studies – Virginia HERNANDEZ-GEA – Spain
